Loading...

KMD

KMD

KAMADA LTD

(KMDA)

2025 6-K

Kamada Filing Update

31 Mar '26

FDA Approval Received

26 Mar '26

Dividend Payment Update

17 Mar '26

Dividend and Growth

11 Mar '26

Kamada Filing Update

4 Mar '26

Kamada Financial Guidance

7 Jan '26

Tender Extension

18 Dec '25

Shareholder Meeting Results

10 Dec '25

Clinical Trial Update

8 Dec '25

Amended Proxy Filing

2 Dec '25

Strong Performance Report

10 Nov '25

Clinical Trial Enrollment

4 Nov '25

Annual Meeting Announcement

23 Oct '25

Investor Conference Announc...

2 Sep '25

Strong Financial Growth

13 Aug '25

FDA Approval Received

11 Aug '25

Kamada Filing Update

6 Aug '25

Business Operations Confirmed

17 Jun '25

Strong Financial Results

14 May '25

Kamada Filing Update

7 May '25

Research Program Launch

5 May '25

Kamada Dividend Update

24 Mar '25

Plasma Collection Expansion

19 Mar '25

Kamada Financial Update

5 Mar '25

Kamada Filing Update

26 Feb '25

Contract Announcement

22 Jan '25

Financial Guidance Update

8 Jan '25

Annual General Meeting

11 Dec '24

Profitable Growth Update

13 Nov '24

Kamada Filing Update

6 Nov '24

Conference Presentation

4 Nov '24

Annual Meeting Notice

21 Oct '24

Plasma Expansion

23 Sep '24

Strong Financial Results

14 Aug '24

Earnings Announcement

7 Aug '24

Strong Financial Results

8 May '24

Kamada Updates

1 May '24

Strong Fiscal Performance

6 Mar '24

Earnings Announcement

28 Feb '24

External Links:

SEC

Kamada Ltd. has announced a $25 million, 3-year contract for the supply of KAMRAB® and VARIZIG® in Latin America, effective as of January 22, 2025. This is considered a significant event for the company.

AI Assistant

KAMADA LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.